SB 239 — Relating to Opioid Addiction Treatment; to repeal the Medication Assisted Treatment of Opioid Use Act of 2019, codified as Sections 20-2-300 through 20-2-302, Code of Alabama 1975, that provide for adoption of rules governing use of buprenorphine in the treatment of opioid addiction and a standing working group to assist in drafting the rules.
Last action — Enacted as 2023-339
-
✓Introduced
-
✓In Committee
-
✓Passed Senate
-
✓Passed House
-
✓To Executive
-
6Enacted
This bill has been enacted into law. Introduced April 25, 2023. Enacted.
Odds of enactment
High chanceBased on the sponsor, cosponsors, and committee posture, this bill has a high chance of becoming law.
Upgrade to see the exact probability and what's driving it.
A statistical estimate from our own model of past outcomes — an insight, not a guarantee. Policymaking is volatile.
Prognosis
-
Enacted
Current position in the legislative process.
-
1 sponsor
1 primary, 0 co-sponsors signed on.
-
Single-party support
Sponsorship is currently within one party (1 R).
-
Cleared a recorded vote
Passed 2 recorded votes so far.
Based on stage, sponsorship breadth, committee status, recorded votes, and cross-state momentum — a description of the observable signals, not a prediction.
Summary
Medication Assisted Treatment of Opioid Use Act, repealed
Bill Text
What changed in the latest version
51 added · 45 removedPlain-language change summary
The updated version of Bill SB 239 repeals the Medication Assisted Treatment (MAT) of Opioid Use Act of 2019, which previously mandated the Alabama Board of Medical Examiners to create rules for using buprenorphine to treat opioid addiction. This change comes in response to recent updates in federal laws and policies concerning opioid treatment that conflicted with the existing state rules. By repealing the MAT Act, the bill aims to simplify treatment regulations and potentially align Alabama's approach with current federal standards. This matters because it could make it easier for healthcare providers to prescribe buprenorphine and help individuals struggling with opioid addiction.
SB239 INTRODUCEDENROLLED KYD6AA-1KYD6AA-2 By Senator Stutts RFD:
25-Apr-23 2023 Regular Session Page 0 KYD6AA-1SB239 04/19/2023Enrolled JCEnrolled, (L)tgwAn 2023-1573Act, 23 4Relating SYNOPSIS:to Opioid Addiction Treatment;
Theto repeal the Medication Assisted Treatment of Opioid Use Act of 20192019, ("MATcodified Act"),as requiresSections the20-2-300 Alabamathrough Board20-2-302, Code of MedicalAlabama Examiners1975, tothat adoptprovide rulesfor governingadoption theof prescribingrules andgoverning use of medicationsbuprenorphine containingin buprenorphinethe totreatment treatof opioid addiction and a standing working group to assist in drafting the nonresidentialrules. setting.
The rules authorized by The MAT Act relate to dosage, screening, therapy, and record-keeping related to treatment with buprenorphine.
A standard working group with members who specialize in addiction is also provided to assist in adoption of the rules.
Since enactment, changes in federal law and policy governing medication-assisted treatment of opioid addiction have created conflicts with the provisions of the MAT Act.
This bill would repeal the MAT Act.
A BILL TO BE ENTITLED AN ACT Relating to Opioid Addiction Treatment;
to repeal the Medication Assisted Treatment of Opioid Use Act of 2019, Page 1 SB239 INTRODUCED codified as Sections 20-2-300 through 20-2-302, Code of Alabama 1975, that provide for adoption of rules governing use of buprenorphine in the treatment of opioid addiction and a standing working group to assist in drafting the rules.
Page 21 SB239 Enrolled ________________________________________________ President and Presiding Officer of the Senate ________________________________________________ Speaker of the House of Representatives SB239 Senate 03-May-23 I hereby certify that the within Act originated in and passed the Senate.
Patrick Harris, Secretary.
House of Representatives Passed:
18-May-23 By:
Senator Stutts Page 2
Action History
-
Enrolled
Sponsors
- Larry Stutts · Primary
Sponsorship breakdown
Export CSV (upgrade) →1 sponsors · 0 co-sponsors · 139 not signed on
Sponsors (1)
Co-sponsors (0)
None.
Not signed on (139)
139 members have not signed on to this bill.
Show all 139 →"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.
Votes
| Party | Yea | Nay | Present | Not Voting |
|---|---|---|---|---|
| Unaffiliated | 5 | 0 | 0 | 0 |
| R | 68 | 0 | 0 | 3 |
| D | 26 | 0 | 0 | 0 |
| Total | 99 | 0 | 0 | 3 |
| % of votes cast | 97% | 0% | 0% | 3% |
How each member voted (102)
| Party | Yea | Nay | Present | Not Voting |
|---|---|---|---|---|
| R | 48 | 0 | 0 | 2 |
| D | 12 | 0 | 0 | 4 |
| Unaffiliated | 0 | 0 | 0 | 2 |
| Total | 60 | 0 | 0 | 8 |
| % of votes cast | 88% | 0% | 0% | 12% |
How each member voted (68)
Subjects
Frequently asked questions
- What does SB 239 do?
- Medication Assisted Treatment of Opioid Use Act, repealed
- Who sponsors SB 239?
- SB 239 is sponsored by Larry Stutts (R).
- What is the current status of SB 239?
- This bill has been enacted into law. Introduced April 25, 2023. Enacted.
- Where can I track SB 239?
- Track SB 239 free on One Click Politics — get push/email alerts when it moves.
Make your voice heard on SB 239
Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.
Stay ahead of SB 239
Last checked for changes 3 months ago · updated continuously
One Click Politics tracks every bill in Congress and all 50 states.
Track this bill →